{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:45:09Z","timestamp":1764654309030,"version":"3.46.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005363","name":"University of Buenos Aires","doi-asserted-by":"publisher","award":["UBACYT 2023 20020220200144BA"],"award-info":[{"award-number":["UBACYT 2023 20020220200144BA"]}],"id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop the orphan drug benznidazole (BNZ) in orally disintegrating tablets, for the neglected disease American Trypanosomiasis (Chagas disease) therapy. Although children are highly affected by this disease, there are no specific commercial pharmaceutical preparations for this age group in Argentina and in many other countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the production process, co-milling in a ball mill was applied to enhance dissolution rates, followed by direct compression. Taste preference and taste masking experiments were conducted in a test panel of adult volunteers. The tablets were fully characterized and their stability and bioavailability determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>The tablets complied with all the quality control prerequisites, their disintegration time was 30\u00a0s, and as a consequence of the intimate mixture with hydrophilic excipients and particle size reduction, BNZ dissolution was improved, reaching 75% in 0.1\u00a0N hydrochloric acid and 62% in simulated salivary fluid, after 5\u00a0min. X-ray diffraction studies showed that BNZ maintained its original crystalline state (form I) in the tablets. The ODTs remained stable for at least 1 year. Oral bioavailability of BNZ of suspensions obtained from the prepared ODTs was comparable with that of pulverized commercial tablets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The developed tablets may improve paediatric Chagas disease therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgaf076","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:38:41Z","timestamp":1754739521000},"page":"1742-1750","source":"Crossref","is-referenced-by-count":0,"title":["Development of benznidazole orally disintegrating tablets for paediatric patients"],"prefix":"10.1093","volume":"77","author":[{"given":"Ferm\u00edn","family":"Ca\u00f1ete Alberdi","sequence":"first","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Tecnolog\u00eda Farmac\u00e9utica II, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Universidad de Buenos Aires, Instituto de Tecnolog\u00eda Farmac\u00e9utica y Biofarmacia (InTecFyB) , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda F","family":"Filia","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Tecnolog\u00eda Farmac\u00e9utica II, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3914-2214","authenticated-orcid":false,"given":"Laura D","family":"Simionato","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Calidad de Medicamentos, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A","family":"Sandrone","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Tecnolog\u00eda Farmac\u00e9utica II, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R","family":"Vega","sequence":"additional","affiliation":[{"name":"Departamento F\u00edsica de la Materia Condensada, Gerencia de Investigaci\u00f3n y Aplicaciones, Centro At\u00f3mico Constituyentes, Comisi\u00f3n Nacional de Energ\u00eda At\u00f3mica y Escuela de Ciencia y Tecnolog\u00eda, Universidad Nacional General San Mart\u00edn , B1650KNA San Mart\u00edn ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Oppezzo","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Farmacolog\u00eda, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"H\u00f6cht","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Farmacolog\u00eda, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego A","family":"Chiappetta","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Tecnolog\u00eda Farmac\u00e9utica II, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Universidad de Buenos Aires, Instituto de Tecnolog\u00eda Farmac\u00e9utica y Biofarmacia (InTecFyB) , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET) , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana S L","family":"Mouri\u00f1o","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Tecnolog\u00eda Farmac\u00e9utica II, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Universidad de Buenos Aires, Instituto de Tecnolog\u00eda Farmac\u00e9utica y Biofarmacia (InTecFyB) , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET) , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-5917","authenticated-orcid":false,"given":"H\u00e9ctor J","family":"Prado","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia y Bioqu\u00edmica, Departamento de Tecnolog\u00eda Farmac\u00e9utica, C\u00e1tedra de Tecnolog\u00eda Farmac\u00e9utica II, Universidad de Buenos Aires , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Universidad de Buenos Aires, Instituto de Tecnolog\u00eda Farmac\u00e9utica y Biofarmacia (InTecFyB) , C1113AAD Buenos Aires ,","place":["Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET) , C1113AAD Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"author":"PAHO\/WHO Pan American Health Organization\/World Health Organization","key":"2025120200421693700_ref1"},{"volume-title":"The Selection and Use of Essential Medicines 2023: Executive Summary of the Report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines; 24\u201328 April 2023","year":"2023","author":"World Health Organization","key":"2025120200421693700_ref2"},{"key":"2025120200421693700_ref3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eimc.2020.04.011","article-title":"Trypanocidal treatment of Chagas disease","volume":"39","author":"P\u00e9rez-Molina","year":"2021","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2025120200421693700_ref4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/jps.23010","article-title":"First century of Chagas\u2019 disease: an overview on novel approaches to nifurtimox and benznidazole delivery systems","volume":"101","author":"Salomon","year":"2012","journal-title":"J Pharm Sci"},{"key":"2025120200421693700_ref5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ijpharm.2018.05.017","article-title":"Polysaccharides-based multiparticulated interpolyelectrolyte complexes for controlled benznidazole release","volume":"545","author":"Garc\u00eda","year":"2018","journal-title":"Int J Pharm"},{"key":"2025120200421693700_ref6","doi-asserted-by":"publisher","first-page":"123640","DOI":"10.1016\/j.jchromb.2023.123640","article-title":"Microextraction by packed sorbent and high-performance liquid chromatography for determination of benznidazole in human plasma","volume":"1219","author":"Diniz","year":"2023","journal-title":"J Chromatogr B"},{"key":"2025120200421693700_ref7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10856-021-06530-w","article-title":"Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier","volume":"32","author":"Moura Ferraz","year":"2021","journal-title":"J Mater Sci Mater Med"},{"key":"2025120200421693700_ref8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1080\/10837450.2019.1615090","article-title":"Orally disintegrating tablets and orally disintegrating mini tablets\u2013novel dosage forms for pediatric use","volume":"24","author":"Comoglu","year":"2019","journal-title":"Pharm Dev Technol"},{"volume-title":"Guidance for Industry. Orally Disintegrating Tablets","year":"2008","author":"FDA Food and Drug Administration","key":"2025120200421693700_ref9"},{"key":"2025120200421693700_ref10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40261-022-01214-x","article-title":"Pharmacokinetics of morphine Sulfate orodispersible tablets and bioequivalence with immediate-release oral morphine sulfate formulations in healthy adult subjects under fasting conditions: single-dose comparative bioavailability studies","volume":"42","author":"Atrux-Tallau","year":"2022","journal-title":"Clin Drug Investig"},{"key":"2025120200421693700_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2021.120354","article-title":"Form quantitation in desmotropic mixtures of albendazole bulk drug by chemometrics-assisted analysis of vibrational spectra","volume":"265","author":"Moroni","year":"2022","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"2025120200421693700_ref12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/tmi.12980","article-title":"Development and in vitro\/in vivo evaluation of a novel benznidazole liquid dosage form using a quality-by-design approach","volume":"22","author":"Santos Souza","year":"2017","journal-title":"Trop Med Int Health"},{"volume-title":"United States Pharmacopeia and National Formulary (USP-NF 2024 Issue 1)","year":"2024","author":"United States Pharmacopeial Convention","key":"2025120200421693700_ref13"},{"key":"2025120200421693700_ref14","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1590\/S0100-40422009000800034","article-title":"Development of dissolution method for benznidazole tablets","volume":"32","author":"Neves de Lima","year":"2009","journal-title":"Quim Nova"},{"key":"2025120200421693700_ref15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/tmi.12508","article-title":"Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients","volume":"20","author":"Garc\u00eda","year":"2015","journal-title":"Trop Med Int Health"},{"key":"2025120200421693700_ref16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.2042-7158.2011.01284.x","article-title":"Development of effervescent tablets containing benznidazole complexed with cyclodextrin","volume":"63","author":"Maximiano","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"2025120200421693700_ref17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijpharm.2012.08.047","article-title":"Development of oral taste masked diclofenac formulations using a taste sensing system","volume":"438","author":"Guhmann","year":"2012","journal-title":"Int J Pharm"},{"volume-title":"Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms","year":"1997","author":"FDA Food and Drug Administration","key":"2025120200421693700_ref18"},{"key":"2025120200421693700_ref19","first-page":"64","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"Moore","year":"1996","journal-title":"Pharm Tech"},{"volume-title":"ICH Harmonized Tripartite Guideline Stability Testing of New Drug Substances and Products Q1A(R2). Current Step 4 Version","year":"2003","author":"ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use","key":"2025120200421693700_ref20"},{"key":"2025120200421693700_ref21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/jps.23448","article-title":"Unexpected performance of physical mixtures over solid dispersions on the dissolution behavior of benznidazole from tablets","volume":"102","author":"Leonardi","year":"2013","journal-title":"J Pharm Sci"},{"key":"2025120200421693700_ref22","doi-asserted-by":"publisher","first-page":"120731","DOI":"10.1016\/j.carbpol.2023.120731","article-title":"Updates on applications of low-viscosity grade hydroxypropyl methylcellulose in coprocessing for improvement of physical properties of pharmaceutical powders","volume":"311","author":"Jin","year":"2023","journal-title":"Carbohydr Polym"},{"key":"2025120200421693700_ref23","doi-asserted-by":"publisher","first-page":"120312","DOI":"10.1016\/j.ijpharm.2021.120312","article-title":"Effect of co-milling on dissolution rate of poorly soluble drugs","volume":"597","author":"Sl\u00e1mov\u00e1","year":"2021","journal-title":"Int J Pharm"},{"key":"2025120200421693700_ref24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10973-011-1371-6","article-title":"Polymorphic screen and drug\u2013excipient compatibility studies of the antichagasic benznidazole","volume":"106","author":"Maximiano","year":"2011","journal-title":"J Therm Anal Calorim"},{"key":"2025120200421693700_ref25","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/jps.22436","article-title":"The use of solid dispersion systems in hydrophilic carriers to increase benznidazole solubility","volume":"100","author":"Neves de Lima","year":"2011","journal-title":"J Pharm Sci"},{"volume-title":"FAQs: &lt;905&gt; Uniformity of Dosage Units","year":"2025","author":"USP United Stated Pharmacopeia","key":"2025120200421693700_ref26"},{"key":"2025120200421693700_ref27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.2042-7158.2012.01473.x","article-title":"Dissolution testing of orally disintegrating tablets","volume":"64","author":"Kraemer","year":"2012","journal-title":"J Pharm Pharmacol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/12\/1742\/64231118\/rgaf076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/12\/1742\/64231118\/rgaf076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:42:24Z","timestamp":1764654144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/77\/12\/1742\/8249989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,9]]},"published-print":{"date-parts":[[2025,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgaf076","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,9]]}}}